Gene therapy for Hemophilia B uses an AAV5 vector to deliver a functional copy of the F9 gene into liver cells, allowing patients to achieve sustained production of functional factor IX and thereby reducing the frequency of bleeding episodes and the need for regular factor IX infusions [6]. The gene discussed is F9; the disease is hemophilia B.